F.A.Z. Exclusive: Biontech is looking for a new CEO primarily in the USA
Biontech is searching for a new CEO in the United States following the announcement of the founders' operational departure from the company.
F.A.S. Exclusive: BioNTech Investors Want to Invest in Şahin and Türeci's New Start-up
The founders of BioNTech, Uğur Şahin and Özlem Türeci, are stepping down from their executive roles to focus on a new start-up, with their investors Thomas and Andreas Strüngmann looking to support this venture.
Unfortunate Timing: BioNTech Executive Sells Shares
BioNTech executive Sierk Poetting sold shares worth seven million dollars just one day after the surprise announcement from the company’s founders about their planned departure.
Biotechnology: The departure of the founders is a disaster for Biontech
The stock price of Biontech plummeted by about 20% following the announcement of founders Uğur Şahin and Özlem Türeci stepping back from the company by the year's end.
Şahin and Türeci: What can be learned from the founders of BioNTech
The founders of BioNTech, Şahin and Türeci, are stepping back from their leadership roles, signaling a new phase in their innovative journey.
Farewell to Sahin and Türeci: A Wise Decision by the BioNTech Founders
Ugur Sahin and Özlem Türeci, founders of BioNTech, are stepping back from daily operations, a decision viewed as part of their strategic foresight.
Farewell to Sahin and Türeci: A Wise Decision by the BioNTech Founders
Ugur Sahin and Özlem Türeci's decision to step back from the operational leadership of BioNTech is seen as a strategic move in their ongoing legacy in pharmaceuticals.
Biontech: 'Heart and Brain'
Uğur Şahin and Özlem Türeci, the co-founders of Biotech company Biontech, will step down from their executive roles at the end of 2026 to start a new venture focused on mRNA and AI.
The two founders of BioNTech leave the pharmaceutical company that won the race for COVID vaccines
The founders of BioNTech, Ugur Sahin and Özlem Türeci, are leaving the company to create a new venture focused on next-generation mRNA medications.
End of an Era at BioNTech: Turkish Co-Founders Depart
The co-founders of BioNTech, Ugur Sahin and Özlem Türeci, are leaving the company to pursue a new venture focusing on next-generation mRNA technology amid rising financial losses for BioNTech.
Pharmaceutical Industry: BioNTech Founders Leave Company
BioNTech founders Uğur Şahin and Özlem Türeci will leave the company by the end of 2026 to start a new biotechnology firm focused on developing the next generation of mRNA-based drugs, while remaining shareholders in BioNTech.
Pharmaceutical industry: BioNTech founders leave the company
BioNTech founders Uğur Şahin and Özlem Türeci will leave the company by the end of 2026 to establish a new biotechnology firm focused on mRNA-based medications while retaining a minority stake in BioNTech.
Pharma Pioneers: Founders Ugur Sahin and Özlem Türeci Leave Biontech
Biontech founders Ugur Sahin and Özlem Türeci are set to leave the company to start a new biopharmaceutical venture focusing on mRNA-based medications.
BioNTech filed a lawsuit against Moderna for patent infringement
BioNTech has sued Moderna in a Delaware federal court, claiming that Moderna's mNEXSPIKE vaccine violates BioNTech and Pfizer's patent for their Comirnaty vaccine.
New study: booster vaccinations reduced severe consequences of COVID-19
A recent study published in the journal 'Vaccine' shows that booster vaccinations significantly decreased the incidence of severe COVID-19 outcomes, with similar efficacy found for Moderna and Pfizer/BioNTech boosters, though protection waned over time.
Hope Against Triple Negative Breast Cancer: Experimental Vaccine Shows Positive Results
An experimental mRNA vaccine shows promising outcomes in a small trial for triple-negative breast cancer patients.
Marburg Special Fund: What is Left from the BioNTech Millions
The city of Marburg has successfully invested a significant portion of its business tax revenues from the pandemic into a special fund, which is now helping to stabilize its budget.
Bayer sues the inventors of the first coronavirus vaccine for a patent
Bayer has filed a lawsuit against Pfizer, Biontech, and Moderna, claiming they copied a technology that Bayer's subsidiary, Monsanto, patented in the 1980s.
Patents: Bayer sues Biontech and Pfizer over COVID vaccines
Bayer is suing Pfizer, Biontech, and Moderna for potential patent violations related to their mRNA vaccines, claiming they copied technology from Bayer's subsidiary, Monsanto.
Financial Policy: The Problem at the Super Exchange
German Chancellor Friedrich Merz advocates for a European stock exchange to compete with the U.S., arguing that larger capital markets may offer better solutions for successful companies.